The PERIOP-OG trial is a prospective and pragmatic randomised controlled multi-centre superiority trial that will compare a programme of peri-operative exercise with standard care in patients with oesophagogastric cancer undergoing NCT followed by surgery. The trial will be conducted in 3 university teaching hospitals in Ireland (Beaumont Hospital, Dublin, The Mercy University Hospital, Cork and Galway University Hospital, Galway) with the exercise training programme delivered in 7 exercise centres nationwide. The exercise training is delivered through ExWell Medical which is a chronic illness exercise and rehabilitation service, and its exercise partners nationwide.
Lead exercise personnel perform assessments after receiving standardised training by lead study coordinators (LL and RT).
An algorithm of the clinical pathway and the timepoints for assessments during the trial is shown in Figure 1. Ethical approval for this study has been received in each participating site prior to study commencement and the trial is registered with clinicaltrials.gov (NCT: NCT0380751).
Study Objectives
The primary objective of the PERIOP-OG trial is to demonstrate that a structured community-based exercise programme will result in a clinically significant increase in cardiorespiratory fitness pre-surgery when compared to a standard care control group. Cardiorespiratory fitness will be assessed using a 6-minute walk test (6MWT) at 5 time points in the study – baseline, post NCT, pre-surgery, 4 weeks and 10 weeks after surgery.
Secondary aims of the study include assessing whether exercise training improves other physical health outcomes assessed using upper and lower body strength tests, activity behavior monitoring, body mass index and frailty. Psychological health will be assessed using a series of questionnaires; HRQoL (EQ-5D-5L Health Questionnaire), Functional Assessment of Cancer Therapy (FACT-E), General Self Efficacy (GSE), Mastery (Pearlin Mastery Scale), Surgical Fear Questionnaire (SFQ) and general optimism using the Life Orientation Test-Revised (LOT-R) tool as well as semi structured interviews.
Exploratory end-points include assessment of post-operative morbidity (Clavien-Dindo classification and as agreed by the Esophagectomy Complications Consensus Group (ECCG) (28), the Comprehensive Complication Index, hospital length of stay, nutritional status (serum albumin, sarcopenia score and Foodbook-24), inflammatory markers, cancer staging and response to NCT and a medico-economics analysis of cost effectiveness of the exercise intervention on reducing health care costs and burden. Additionally, rates of NCT toxicity, tolerance and compliance will be measured.
Participants
Eligibility criteria include the following: age ≥ 18 years, multidisciplinary team (MDT) referral for neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy prior to oesophagectomy or gastrectomy; confirmed adenocarcinoma or squamous cell cancer of the oesophagus, oesophago-gastric junction or stomach; for oesophageal cancers tumours must be more than 5cm below the crico-pharyngeus muscle.
Exclusion criteria include the following: inability to give informed consent, inability to participate in exercise training (unable to perform 6MWT); patients undergoing primary surgery; distant metastatic disease, previous or concomitant malignancy that would interfere with this treatment protocol and pregnancy.
Recruitment and randomisation
The PERIOP-OG trial is currently recruiting (start date 1st March 2019, proposed end date July 2020). All potentially eligible patients are identified in each centre’s MDT and are approached for inclusion at diagnosis before NCT has started. Eligible patients are given an information leaflet and then 72 hours later are contacted to confirm participation, informed consent is taken and randomisation group revealed. Participants are randomised using central data management to generate a random allocation sequence (1:1). Due to the nature of the study, blinding of patients, data collectors and physiological assessors is not possible but treating surgeons and their teams are blinded to randomisation, as is the primary analyst.
Nutrition
Malnutrition is common in patients diagnosed with oesophagogastric cancers. All participants enrolled in the PERIOP-OG trial follow a standardised nutritional pathway of care. All 3 participating centres have specialist dieticians who are highly trained and dedicated to the care of oesophagogastric cancer patients. All patients have a dietician assessment at the time of diagnosis and an individualised dietary plan with appropriate supplementation structured to ensure sufficient calorie and protein supplementation. Pre- and peri-operative feeding adjuncts (percutaneous enteral feeding or total parenteral nutrition) will be recorded on an individual basis.
Usual care control group
The usual care control group (no formal exercise training) receive routine care throughout their cancer pathway. No specific advice about exercise training is offered. Activity monitors are worn for a period of 7 days by patients in both groups at each time point of assessment and are used to measure the exercise levels of patients within the control group.
Exercise intervention group
The exercise-training programme is started before and continues during NCT. It is continued between NCT and surgery and then resumed for 6 weeks after surgery once patients are deemed clinically fit. The exercise-training programme is based on experience gained from a previous feasibility study performed by our own team.
Participants in the exercise group can participate in either a centre-based exercise programme (CBEP) or a home-based exercise programme (HBEP). All participants in the exercise group are provided with a fitbit and a step count log.
The HBEP is offered for patients where access to an exercise centre is difficult due to remote or rural living. HBEP involves undertaking exercise independently and is prescribed at the baseline assessment (Figure 1). Patients are given a home programme pack, which includes a manual exercise handbook, an exercise prescription, a rate of perceived exertion (RPE) scale and a log diary. They are also given a link to an online motivational video developed specifically for the PERIOP-OG Home Programme. Participants are educated in aerobic and resistance exercises and the RPE scale and they complete a 10-minute exercise session on the cycle ergometer under the supervision of their personal trainer. This provides an understanding of what exercise intensity level they should aim to achieve during aerobic exercise at home. Additionally, participants are instructed on resistance exercises (i.e. weight selection, technique, breathing, rest periods). HBEP participants receive a weekly telephone call, using a structured proforma, to assess adherence to the programme and to amend the programme if necessary. Participants feedback their daily step count each week. All conversations and the duration of each phone call are documented in participant case report forms. HBEP compliance is also self-reported by the participant using a log diary.
The CBEP takes place in 7 exercises centers nationwide. Participants are prescribed exercise on an individual basis following the principles below. Compliance with the CBEP is recorded by number of sessions attended.
Exercise training protocol
The delivery of the CBEP and HBEP is described using the FITT principle (frequency, intensity, time and type of exercise training) (29).
Frequency - Participants are asked to undertake 2-3 structured exercise training sessions per week during NCT and 3 thereafter.
Intensity - Exercise sessions may be interval based or continuous. Interval training involves a series of exercises repeated at moderate and higher intensities and continuous exercise sessions involve moderate intensity continuous exercise for the entire duration of the exercise period.
Participants in either programme with access to gym equipment engage in interval training of moderate and high intensity (13: somewhat hard to 15: hard on the RPE scale). For those unable to undertake interval training or with no access to gym equipment, a continuous exercise training programme is prescribed based on the RPE scale (13: somewhat hard).
Time –The first interval (moderate to high intensity) exercise session is 30 minutes: 5-minute warm-up followed by 4 repeated bouts of moderate intensity (3 min) to high intensity (2 min) intervals and 5-minute cool down. The first continuous exercise session is also 30 minutes duration: 5 minutes warm-up, 20 minutes of continuous moderate intensity exercise and 5 minutes cool down.
The second and subsequent sessions are 40 minutes long: 5 minutes warm-up followed by 6 repeated bouts of moderate intensity (3 minutes) to high intensity (2 minutes) intervals and a 5 minute cool down. The second continuous exercise session is made up of a 5-minute warm-up, 30 minutes of continuous moderate intensity and a 5-minute cool down. Post-operatively, participants resume exercising initially for 20-minute sessions and increase the duration of exercise by 10 minutes per week until the pre-operative timings are achieved.
Type - CBEP or HBEP participants with access to gym equipment may include the use of any of the following equipment: upright cycle ergometer; recumbent cycle ergometer; treadmill; elliptical ergometer; and rowing ergometer, depending on patient preference. HBEP participants without gym access, may use a combination of walking, jogging or cycling.
Resistance training involves a circuit of 6-10 stations alternating upper and lower body exercises using dumb-bells as outlined in the home-based exercise manual handbook.
Progression - During NCT, there is no progression in exercise intensity. In the time window between completing NCT and surgery, exercise intensity is progressed every 5 sessions. Post-operatively, exercise is progressed by time (as previously outlined) and also by intensity 8 weeks following surgery.
Outcome Measurements
Table 1 demonstrates the time points at which each outcome measure is assessed in the PERIOP-OG trial.
Primary Outcome:
Cardiorespiratory Fitness
The primary outcome is measurement of cardiorespiratory fitness using the 6MWT measured at baseline assessment and prior to surgery. The 6MWT is performed with participants walking up and down a 20 meter course marked by cones for 6 minutes under instruction to cover as much ground as possible. The number of laps completed is recorded. A standard set of instructions is used as per the European Respiratory Society guidelines. The 6MWT is a validated assessment of cardiorespiratory function in clinical populations (30, 31). A systematic review in 2016 demonstrated that field tests may be able to predict post operative outcome however further validation work is merited (32).
Secondary Outcomes:
Physical Health
Strength:
i) The sit to stand test. Participants sit on a chair (height 43-45 cm) with arms crossed across their chest, feet flat on the floor, parallel to each other, and approximately shoulder width apart. Participants then stand up and sit down 10 times as quickly as possible and must fully extend their legs on each stand. The time taken to perform 10 repetitions will be timed. Participants will perform two trials and the best trial will be recorded as their score (33).
ii) The handgrip test. This is measured using a hand dynamometer (Takei 5401 Hand Grip Dynamometer (Digital)). The test is conducted in a standing position with the upper arm tight against the participant’s trunk and the forearm at a right angle to the upper arm. The gripping handle is set to a comfortable width to ensure the participant can rest the fat pads of the phalanx of the four fingers on the handle. The participant is instructed to squeeze the handle with maximum force for 5 seconds and the value recorded. The participant will complete three trials on each hand. The highest score will be recorded (34).
Activity Behavior
Physical activity and sedentary behavior is assessed using a 7-day ActivPAL3 triaxial accelerometer. Participants in both groups are instructed to wear this device on the midpoint of the anterior aspect of the right thigh continuously for seven days at the 5 time points of assessment. Total activity counts per day as well as time in sedentary behavior are recorded for both groups.
Body Composition
BMI is calculated in the standard manner.
Frailty
Fraility is assessed by the Risk Analysis Index. It has been reported as a valid tool for measuring frailty in surgical populations (35). It provides a prospective, pre-operative assessment of frailty in clinical practice. It provides a score between 0 and 81 taking into account demographic, clinical and independence information.
Psychological Health:
This is assessed using a number of validated questionnaires and semi-structured interviews. The questionnaires are as follows;
- Life Orientation Test-Revised (LOT-R) – Assesses optimism and consists of ten items assessing expectancy of positive versus negative outcomes. Higher scores represent higher levels of optimism (36).
- EQ-5D-5L health questionnaire is a standardised measure of health status developed by the EuroQoL Group in order to provide a simple, generic measure of health for clinical and economic appraisal (37).
- Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire. This is a health-related quality of life instrument validated in patients with esophageal cancer. It is composed of a general component (FACT-G) and an esophageal cancer subscale (ECS) (38).
- The Surgical Fear Questionnaire (SFQ) will assess participants fear of surgery and is a validated and reliable eight-item index of surgical fear consisting of 2 subscales: fear of the short-term consequences of surgery and fear of the long-term consequences of surgery (39).
- General Self Efficacy (GSE) and Mastery (Pearlin Mastery Scale). A highly reliable and validated measurement of self-efficacy. This questionnaire consists of seven items designed to assess psychological coping resources (Mastery) (40).
- Semi-structured interviews will explore patients’ perceptions of the surgical pathway.
Exploratory outcomes will include:
Nutritional Status is assessed using the following tools:
- Glasgow Prognostic Score provides cancer prognosis based on serum biomarkers CRP and Albumin (41).
- Foodbook-24, a web-based, dietary tool consisting of a 24 hour dietary recall and food frequency questionnaire (42).
- Sarcopenia – Standard care for all patients is to undergo a staging CT scan at the time of diagnosis and then a restaging CT scan after NCT. Sarcopenia will be measured at these 2 time points using SliceOmatic software (Tomovision, Magog, Canada). At the L3 level total skeletal muscle, subcutaneous fat and visceral fat will be measured. Skeletal muscle mass will be calculated as skeletal muscle / height (m)2 and will be recorded by two individuals, both of whom will be external to the trial group.
Post-operative Morbidity Outcomes
i. Post-operative Morbidity Score (POMS) is an 18-item tool that addresses morbidity relevant to the post-surgical patient (43).
ii. The Clavien-Dindo classification of surgical complications consists of 7 grades that rank post-operative complication severity (44).
iii. The Comprehensive Complication Index (45) integrates all post-operative complications with their respective severities, on a scale ranging from 0 (no burden from complications) to 100 (death).
iv. Patients undergoing oesophagectomy will have post-operative morbidity recorded as per the Esophagectomy Complications Consensus Group (28) mortality will be assessed at 30 days and 90 days.
Blood Markers of Inflammation
C- reactive protein and white cell count will be measured.
Health Economic Outcomes
An exploratory analysis will be made of the cost of the exercise intervention and the net monetary benefit on health care costs and health care interactions arising during the time period of the study will be calculated.
NCT Toxicity
Rates of NCT toxicity, tolerance and compliance will be collected.
Patient and Public Involvement (PPI)
Patient and public volunteers are members of the trial steering committee and their experience and input was used to help shape the study design. Volunteers attend quarterly trial steering meetings and receive monthly newsletters and trial management meeting minutes. They will assist with trial delivery and conduct as well as trial reporting. Additionally, they guide our dissemination plan using social media, presentation at conferences, dissemination to patient advocacy groups and journal articles.
Safety
Adverse events are recorded in the relevant case report form by the lead site researcher. Fatal or life-threatening serious adverse events are reported within 24 hours of the research team becoming aware of the event. The serious adverse events form documents the nature of the event, date of onset, severity, corrective therapies given, outcome and causality (i.e. unrelated, unlikely, possibly, probably, definitely). Any queries relating to adverse event reporting will be directed to the principal investigator.
Data analysis
Sample size calculation
The sample size calculation was based on results from a recent publication by Minnella et al (46) which identified a pre-operative increase in 6MWT of 60m from a baseline score of 450m - an approximate 13% improvement. Assuming a similar baseline score, a 15% difference can be detected with a p-value of 0.05 and power 80% with a sample of 26 participants with full data in the 2 groups. With an anticipated 20% drop out, recruitment of 62 participants is anticipated.
Stastistical Analysis
The analysis will be performed as an intention-to-treat analysis. No interim analysis will be conducted. Data validity will be conducted prior to analysis and corrected as appropriate.
The study population will be described separately for the two randomised groups using variables obtained at baseline. The variables will be described as mean (SD) and numbers (%) as appropriate.
The primary analysis of the primary outcome will be conducted using t-tests of independent group mean differences in 6MWT. The mean difference and 95% confidence interval will be reported and illustrated graphically. Individual change in 6MWT will be calculated from baseline and compared at different time points using t-tests.
The secondary analysis of the primary outcome will use mixed-level analysis with intervention group, time point and interaction of intervention and time points. This analysis will include baseline score for the outcome measure as a covariate. The estimated parameter for the interaction variables will be interpreted as the difference-in-difference between the two groups over time. A separate analysis will explore potential differences in the intervention group between participants who received the intervention at a training centre and those who trained at home. This analysis will be expanded to include descriptive baseline variables such as sex and age. The secondary analysis will use mixed-level analysis and include baseline score and baseline characteristics as covariates.
The cost-effectiveness analysis will be conducted from a societal perspective over the duration of the trail period. No extrapolation of long-term economic outcomes is planned. The EQ-5D-5L data reported at each time point will be used to estimate quality-adjusted life years using time-weighted utility scores. The utility scores will be calculated for each individual at each data point using the Irish scoring algorithm for EQ-5D-5L (47). The area under the curve denotes the QALY and incremental QALY is determined as the mean group difference.
Cost of the intervention and subsequent health care resource use will be calculated for each individual using average cost per participant for the intervention programme and self-reported data on healthcare utilisation. Unit costs will be obtained from national sources and assigned to the resource utilisation and aggregated over the whole trial period for each individual. Net monetary benefit (NMB) will be estimated as the cost minus the QALY gain multiplied by an assumed threshold value per QALY.
Missing data
Participants with missing data either because of early drop-out, loss to follow-up or missed participation in the data collection can bias the results. By design there will be no missing data at baseline because only participants with complete baseline data will be randomised.
Missing variables in outcome measures will be handled according to instrument developers’ guidelines. As a general rule, if more than 20% of the items of an instrument are missing the summary score will be assigned as missing. Missing data will be reported as part of the summary presentation of the raw data. Logistic regression will be used to explore whether participants with missing data have different characteristics than the completers or whether missing data can be assumed missing by random.
Procedures for data checking and entering
Data will be double data entered, and data validation will take place according to the procedures set out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.
The Standard Protocol Items-Recommendations for Interventional Trials (SPIRIT) table provides an overview of the study conduct, review, reporting and interpretation and is presented in Table 2. The final report will follow the Consolidated Standards of Reporting Trials (CONSORT), as well as the Template for Intervention Description and Replication (TIDieR).
Table 2.The Standard Protocol Items-Recommendations for Interventional Trials (SPIRIT)
Section/item Item No Description Addressed on page number
|
Administrative information
|
|
Title
|
1
|
The effect of a pre- and post- operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial.
|
1
|
Trial registration
|
2a
|
ClinicalTrials.gov Identifier: NCT03807518
|
4
|
2b
|
N/A
|
|
Protocol version
|
3
|
1st November 2019 Version 2
|
4
|
Funding
|
4
|
Beaumont Hospital Foundation Trust
|
25
|
Roles and responsibilities
|
5a
|
WR, NMcC, LL conceived the study. WBR, NMcC, PAC, MA, TJM, CGC, OM, LL, RT, JB, PG, CT and JS contributed to study design. WR, RT, LL and JB drafted the manuscript, which underwent revision by all other authors.
|
25
|
5b
|
Royal College of Surgeons Ireland, 123 St Stephens Green, Dublin, Ireland
Sponsor had no role in study design
|
1
|
|
5c
|
Mr. William Robb, Principal Investigator
Dr. Noel McCarrfey, Co Investigator
Mr. Thomas Murphy, Co Investigator
Mr. Chris Collins, Co Investigator
Prof. Oliver McAnena, Co Investigator
Mr Paul A Carroll, Co Investigator
Dr. Lisa Loughney, Coordinator and exercise lead
Dr. Roisin Tully, Coordinator
Mr. Jarlath Bolger, Recruiting and consenting patients
Mr Mayilone Arumugasamy Co Investigator
Prof. Pamela Gallagher, Psychological lead
Dr. Claire Timon, Nutritional lead
Prof. Niall Moyna, Exercise specialist
Prof. Jan Sorensen, Health Economist
|
1
|
|
5d
|
Steering committee: William Robb, Thomas Murphy, Lisa Loughney, Roisin Tully
Data management team: Lisa Loughney, Roisin Tully, Jan Sorenson, Jarlath Bolger
|
|
Introduction
|
|
|
|
Background and rationale
|
6a
|
Oesophagogastric cancers are a considerable health burden. In the past 10 years the 5-year survival for both cancers has doubled. This is due to a number of factors including advances in neoadjuvant and adjuvant chemotherapy and radiotherapy. However, physical fitness significantly declines as a result of neoadjuvant and adjuvant therapy. From studies in other cancers it is known that peri operative training improves physical fitness, yet there is little research into its effects in those with upper oesophagogastric cancers. Therefore, the aim of the PERIOP-OG trial is to investigate the effects of a community-based exercise training programme (delivered in a leisure centre or at home dependent on patient location) pre- and post– operatively compared to usual care on cardiorespiratory fitness and other physical, psychological and clinical health outcomes in people with confirmed oesophagogastric cancer.
|
5
|
|
6b
|
The usual-care control group (usual care – no formal exercise training) receive routine care throughout their cancer pathway from diagnosis to surgical resection. No specific advice about exercise training is offered.
|
9
|
Objectives
|
7
|
The aims of this study were to evaluate the following hypotheses:
Primary hypothesis: A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in a clinically significant increase in cardiorespiratory fitness assessed using a 6-minute walk test assessed at the pre-surgery time point.
Secondary hypothesis:
a) A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement in cardiorespiratory fitness post-operatively in addition to other physical health outcomes assessed using upper and lower body strength tests, physical activity monitoring, body mass index, frailty assessed at several time points throughout the study.
b) A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement psychological health assessed using health related quality of life questionnaire and semi structured interviews assessed at several time points throughout the study.
Exploratory hypothesis: A structured community-based exercise programme compared with a usual care control group (usual care – no formal exercise training) will result in an improvement in health economy assessed using a questionnaire and clinical health assessed using post-operative morbidity and hospital length of stay, nutritional status, immune and inflammatory markers, as well as cancer staging assessed at several time points throughout the study.
|
7
|
Trial design
|
8
|
Parallel group randomised 1:1 controlled multi centre trial.
|
9
|
Methods: Participants, interventions, and outcomes
|
|
Study setting
|
9
|
There are three Irish Health Services Executive (HSE) hospitals recruiting to this trial: Beaumont Hospital Dublin, Mercy University Hospital Cork (MUHC) and University Hospital Galway (UHG). Assessments and exercise training is being delivered in several sites. For Beaumont hospital Dublin: ExWell Medical; for MUHC, to cater for a large area: Cork Leisure World, Waterford Institute of Technology, Heartwise for Health and University of Limerick; and for UHG, Cancer Care West gym.
|
7
|
Eligibility criteria
|
10
|
Eligibility criteria for inclusion at cancer diagnosis include the following: age ≥ 18 years, with multidisciplinary team (MDT) referral for neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy (NCT) prior to planned oesophagectomy or gastrectomy; with confirmed MDT evidence of adenocarcinoma or squamous cell cancer of the oesophagus, oesophago-gastric junction or stomach requiring planned surgical resection; with recorded measurement (endoscopic or otherwise) that the tumour starts more than 5cm below crico-pharyngeus. Exclusion criteria include the following: inability to give informed consent, inability to participate in exercise training (unable to perform 6MWT, patients with high grade dysplasia (squamous cell or adenocarcinoma); distant metastatic disease at time of enrolment or during their NCT therapy; Evidence of previous/concomitant malignancy that would interfere with this treatment protocol; Pregnancy. Figure 1 provides an algorithm of the clinical pathway and complete series of assessment for the duration of the trial.
|
8
|
Interventions
|
11a
|
Participants are randomised (1:1) to either a structured exercise training programme or usual care control group at baseline
|
9
|
11b
|
The intervention will be discontinued for a given participant should they no longer wish to participate.
|
10
|
11c
|
Strategies to improve adherence to intervention protocols. The participants will meet the instructors face to face at the structured exercise sessions. Additionally, they will receive phone calls from the team to monitor their progress and answer any questions they may have on a regular basis.
|
10
|
11d
|
All routine cancer care is permitted for both groups
|
9
|
Outcomes
|
12
|
The primary endpoint is cardiorespiratory fitness measured by the 6-minute walk test assessed at the pre-surgery time point. Secondary endpoints include measurement of cardiorespiratory fitness measured post operatively and physical health assessed using upper and lower body strength tests, physical activity monitoring, body mass index, frailty, psychological health: assessed using health related quality of life questionnaire and semi structured interviews. Exploratory endpoints include health economy and clinical health assessed using post-operative morbidity and hospital length of stay, nutritional status, immune and inflammatory markers, as well as cancer staging.
|
13
|
Participant timeline
|
13
|
Outcome measurements are taken for all participants at baseline, post NCT, pre surgery, 3 days post-surgery, 5 days post-surgery, 4 weeks post-surgery and 10 weeks post-surgery.
|
7
|
Sample size
|
14
|
The sample size calculation was based on results from the Minnella et al, study which identified a pre-operative score gain in 6MWT of 60m from a baseline score of 450m (standard deviation 85m) an approximate 13% improvement. Assuming a similar baseline score, a 15% score gain can be detected with p-value of 0.05 and power 80% with a sample of 26 participants with full data in 2 groups. With an anticipated 20% drop-out, recruitment of 62 participants is anticipated.
|
18
|
Recruitment
|
15
|
Inclusion of 3 clinical sites and 7 exercise sites with the additional option of a home programme.
|
7
|
Methods: Assignment of interventions (for controlled trials)
|
|
Allocation:
|
|
|
|
Sequence generation
|
16a
|
Randomisation is performed using a central data management to generate a random allocation sequence (1:1).
|
9
|
Allocation concealment mechanism
|
16b
|
Randomization allocation and areas stored in opaque envelops at the lead exercise site (ExWell Medical, Dublin). Due to the nature of the study, blinding of patients or physiological assessors is not possible.
|
9
|
Implementation
|
16c
|
Randomisation is generated by the lead coordinator and exercise lead (LL).
|
9
|
Blinding (masking)
|
17a
|
Due to the nature of the intervention, it will not be possible to blind the participants.
|
9
|
|
17b
|
Unblinding will not be permissible
|
9
|
Methods: Data collection, management, and analysis
|
|
Data collection methods
|
18a
|
The outcomes are listed in Table 1: Outcomes and Assessment Measures.
|
13
|
|
18b
|
The participants are contacted by telephone curing the intervention to promote participant retention and complete follow-up. Baseline data to be collected for participants who discontinue or deviate from intervention protocols, unless they withdraw consent.
|
13
|
Data management
|
19
|
Data will be double data entered, and data validation will take place according to the procedures set out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.
|
20
|
Statistical methods
|
20a
|
The analysis will be performed as an intention-to-treat analysis. No interim analysis will be conducted. Data validity will be conducted prior to analysis and corrected as appropriate. This includes tabulation of discrete score values and graphical representation of continuous variables (e.g. histograms and box plots).
The study population will be described separately for two randomised groups using variables obtained at baseline. The variables will be described as mean (SD) and numbers (%) as appropriate.
The primary analysis of the primary outcome will be conducted as t-tests of independent group mean differences in 6MWT at each time point. The mean difference and 95% confidence interval will be reported and illustrated graphically. Individual change in 6MWT will be calculated from baseline and compared at different time points using t-tests. In addition, binary outcome variables indicating ability of walk more than the combined median distance at baseline will be constructed and the group distribution will be tested at different time points using chi-squared tests.
|
18
|
|
20b
|
The secondary analysis of the primary outcome will use mixed-level analysis with intervention group, time point and interaction of intervention and time points. This analysis will include baseline score for the outcome measure as covariate. The estimated parameter for the interaction variables will be interpreted as the difference-in-difference between the two groups over time. A separate analysis will explore potential differences in the intervention group between participants who received the intervention at a training centre and those who trained at home. This analysis will be expanded to include descriptive baseline variables such as sex and age. The secondary analysis will use mixed-level analysis and include baseline score and baseline characteristics as covariates.
The cost-effectiveness analysis will be conducted from a societal perspective over the duration of the trial period. No extrapolation of long-term economic outcomes is planned. The EQ-5D-5L data reported at each time point will be used to estimate quality-adjusted life years using time-weighted utility scores. The utility scores will be calculated for each individual at each data point using the Irish scoring algorithm for EQ-5D-5. The area under the curve denotes the QALY and incremental QALY is determined as the mean group difference.
Cost of the intervention and subsequent resource use will be calculated for each individual using average cost per participant for the intervention programme and self-reported data on healthcare utilisation. Unit costs will be obtained from national sources and assigned to the resource utilisation and aggregated over the whole trial period for each individual. Net monetary benefit (NMB) will be estimated as the cost minus the QALY gain multiplied by an assumed threshold value per QALY. The NMB estimates will also be analysed using regression methods to account for variation in group characteristics and to identify sub-populations where the intervention might have incremental cost-effectiveness ratio.
|
|
|
20c
|
Participants with missing data either because of early drop-out, loss to follow-up or missed participation in the data collection can bias the results. By design there will be no missing data at baseline because only participants with complete baseline data will be randomised.
Missing variables in outcome measures will be handled according to instrument developers’ guidelines. As a general rule, if more than 20% of the items of an instrument are missing the summary score will be assigned as missing.
Missing data will be reported as part of the summary presentation of the raw data.
Logistic regression will be used to explore whether participants with missing data have different characteristics than the completers or whether missing data can be assumed missing by random. If a pattern in missing data can be observed missing data will be handled using “multiple imputation” techniques where missing variables are predicted in multiple dataset using descriptive variables identified as important covariates for missing data (sex, age, intervention group and baseline score).
|
19
|
Methods: Monitoring
|
|
Data monitoring
|
21a
|
Data is monitored after the first complete patient at each site to ensure high quality data. Data will be double data entered, and data validation will take place according to the procedures set out in the data management plan and data validation plan. Prior to any statistical analysis, all variables will be checked for the number of missing values, impossible values and improbable values. Impossible and improbable values will be defined by clinical opinion. Improbable values will also include values that are outside three standard deviations of the mean value. Any questions regarding the data will go back to the data manager. Descriptive statistics will be calculated for all variables, and distributional assumptions will be checked.
|
20
|
|
21b
|
There will be no interim analysis conducted.
|
18
|
Harms
|
22
|
Adverse events will be recorded in the relevant case report form by the researcher. Fatal or life-threatening serious adverse events are reported within 24 hours of the research team becoming g aware of the event. The serious adverse events form documents the nature of the event, date of onset, severity, corrective therapies given, outcome and causality (I.e. unrelated, unlikely, possibly, probably, definitely). And queries relating to adverse event reporting will be directed to the chief investigator in the first instance.
|
17
|
Auditing
|
23
|
Will comply completely with any auditing processes required by sponsor.
|
17
|
Ethics and dissemination
|
|
Research ethics approval
|
24
|
Beaumont Hospital Ethics (Medical Research) Committee REC Ref: 18/58
Dublin City University Research Ethics Committee Ref: DCUREC/2018/255
University Hospital Galway Clinical Research Ethics Committee Ref: C.A 2160
Mercy Hospital Cork CREC Review Reference Number: ECM 4 (mm) 19/04/19
Waterford Institute of Technology REF:WIT2019REC0011
|
24
|
Protocol amendments
|
25
|
All site leads will be contacted by telephone if there is a significant amendment to the protocol. The amended protocol will then be emailed to all site leads.
|
|
Consent or assent
|
26a
|
The study will be discussed with patients after their initial diagnosis is known, but before neo-adjuvant treatment has started. No patient will have the study discussed with them on the day that they find out their diagnosis. Potentially eligible patients will have the study discussed with them by the principal investigator, or a nominated senior non-consultant hospital doctor at their next OPD appointment. Interested patients will receive an information leaflet and consent form for the study. After a period of 48hours, patients will be contacted by telephone to confirm their interest in the study. Consent forms will be signed at their patient visit.
|
25
|
|
26b
|
Additional explicit consent will be sought for collection and use of participant data and biological specimens in ancillary studies.
|
25
|
Confidentiality
|
27
|
Data will be entered with all direct patient identifiers removed; patients will be identified by study codes. All physiological data are held in an encrypted format. All data will be stored on a secure password protected desktop in a secured locked room.
|
20
|
Declaration of interests
|
28
|
The authors declare that they have no competing interests
|
25
|
Access to data
|
29
|
The data will only be accessed by the designated members of the research team.
|
|
Ancillary and post-trial care
|
30
|
Post-trial the structured exercise classes will continue and participants may continue to use the facilitates
|
|
Dissemination policy
|
31a
|
The results will be published in peer reviewed journals and disseminated at conferences and scientific meeting internationally. The findings of the trial will also be published in patient information magazines and booklets as informed with the help of the patient public involvement group.
|
|
|
31b
|
Authorship eligibility guidelines will be discussed and agreed with all contributors prior to publication and the use of professional writers is not intended.
|
|
|
31c
|
There are no plans for granting public access to the full protocol, participant-level dataset, and statistical code
|
|
Appendices
|
|
|
|
Informed consent materials
|
32
|
Model consent form and other related documentation given to participants and authorised surrogates
|
|
Biological specimens
|
33
|
Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable (N/A)
|
NA
|
|
|
|
|
|
|